Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing agreements and losses in civil court actions in the US and Bulgarian court systems, erroneously and maliciously asserted claims to ITV-1 in his attempt to mislead the investing public and to harm the shareholder value of SAGA as well as the Company. The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of Sagaliam.
ALLEN, TX / ACCESSWIRE / 2024年7月26日 / Enzolytics,Inc.(OTC PINK:ENZC)(enzolytics.com)(“公司”)今天表示,公司將全力支持Sagaliam Acquisition Corp(“SAGA”)在其阻止NIKA製藥及其首席執行官Dimtar Savov假稱享有針對Harry H. Zhabilov和Zhabilov信託基金髮行的HIV/AIDS免疫療法專利權的另一次嘗試的所有努力。自從Savov在授權協議上拖欠並在美國和保加利亞法院的民事訴訟中虧損以來,他錯誤並惡意地宣稱對ITV-1的主張,試圖誤導投資公衆並損害SAGA以及公司的股東價值。這項知識產權的獨家許可證持有人是Sagaliam的全資子公司Virogentics,Inc。Steve Sharabura,Enzolytics臨時首席執行官,評論道:“我和董事會堅定地與Sagaliam保持一致,終結這場悲劇並保護兩個實體的股東價值。”關於Enzolytics,Inc. Enzolytics,Inc.正在過渡,從一家致力於推廣其專有蛋白質和單克隆抗體以治療令人嚴重困擾的傳染病的藥物開發公司,轉變爲致力於醫療設備、醫療測試和營養保健產品的銷售、營銷和分銷實體。 Enzolytics,Inc. Steve Sharabura,首席執行官 X / Twitter:@EnzolyticsInc
Sagaliam press release issued on July 25, 2017:
Sagaliam 於 2017年7月25日發佈的新聞稿:
Steve Sharabura, Interim CEO of Enzolytics, commented, "I and the Board of Directors are steadfastly aligned with Sagaliam to bring to an end this travesty and the protection of both entities' shareholder value."
Steve Sharabura,Enzolytics臨時首席執行官,評論道:“我和董事會堅定地與Sagaliam保持一致,終結這場悲劇並保護兩個實體的股東價值。”
About Enzolytics, Inc.
關於Enzolytics,Inc。 Enzolytics,Inc.正在過渡,從一家致力於推廣其專有蛋白質和單克隆抗體以治療令人嚴重困擾的傳染病的藥物開發公司,轉變爲致力於醫療設備、醫療測試和營養保健產品的銷售、營銷和分銷實體。
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to a sales, marketing and distribution entity focusing on medical devices, medical testing and nutraceutical products.
關於Enzolytics,Inc。 Enzolytics,Inc.正在過渡,從一家致力於推廣其專有蛋白質和單克隆抗體以治療令人嚴重困擾的傳染病的藥物開發公司,轉變爲致力於醫療設備、醫療測試和營養保健產品的銷售、營銷和分銷實體。 Enzolytics,Inc。 Steve Sharabura,首席執行官 X / Twitter:@EnzolyticsInc
Forward Looking Statements
前瞻性聲明
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
本披露中包括某些聲明,這些聲明不是歷史事實,但是是根據1995年美國私人證券訴訟改革法案下的安全港規定的前瞻性聲明。通常,前瞻性聲明伴隨着“相信”、“可能”、“將”、“估計”、“繼續”、“預期”、“應該”、“願望”、“計劃”、“預測”、“潛力”、“看起來”、“尋求”、“未來”、“展望”和類似表達趨勢的詞語,或者預測或指示未來事件或趨勢的表達,或者不是歷史事實的聲明。這些前瞻性聲明僅用於說明目的,並且並不旨在作爲任何投資者的保證、保障、預測或確切的事實或概率聲明,任何投資者不得依賴這些聲明。實際事件和情況很難或不可能預測,並且將有所不同。許多實際事件和情況超出了公司的控制範圍。這些前瞻性聲明還受到許多風險和不確定性的影響,包括:公司能否進入有關潛在交易的確定性協議或完成交易;公司的股東能否獲得有關所有潛在交易的批准;由於將潛在交易達成協議或整合公司的業務而未能實現預期的收益;公司股東提出的贖回請求的數量以及滿足此類請求後公司信託帳戶內剩餘的資金數量;公司提交給SEC的10-K年度報告中討論的因素,以及公司已提交或將提交給SEC的其他文件。如果這些風險成爲現實或假設被證明不正確,則實際結果可能會與這些前瞻性聲明所暗示的結果有所不同。還可能存在公司目前不知道或公司目前認爲不重要的其他風險,可能導致實際結果與前瞻性聲明中所包含的結果有所不同。另外,前瞻性聲明反映公司管理層對未來事件和展望的期望、計劃或預測,以及自本日以來的觀點。公司預計後續事件和發展將導致公司的評估發生變化。然而,雖然公司可能在未來某個時間選擇更新這些前瞻性聲明,但公司明確聲明沒有任何義務這樣做。因此,不得將這些前瞻性聲明作爲代表公司評估的任何日期之後的任何日期。因此,不應過度依賴前瞻性聲明。
CONTACT INFORMATION
聯繫信息
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
Enzolytics,Inc。
Steve Sharabura,首席執行官
3002 Royal Palm
Baytown, Texas 77523
電話:(845) 925-4597
X / Twitter:@EnzolyticsInc
SOURCE: Enzolytics, Inc.
來源:Enzolytics,Inc。